Meeting
2013 ASCO Annual Meeting
Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).
Authors
Farrah Mikhail Datko
Memorial Sloan-Kettering Cancer Center, New York, NY
Farrah Mikhail Datko , Gabriella D'Andrea , Maura N. Dickler , Shari Beth Goldfarb , Maria Theodoulou , Diana Lake , Monica Nancy Fornier , Shanu Modi , Julie Fasano , Elizabeth Anne Comen , Devika Gajria , Mary Ellen Moynahan , Tiffany A. Traina , Melanie Chen , Nicola Hamilton , Sujata Patil , Sarat Chandarlapaty , Clifford Hudis , Chau T. Dang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT01276041
Citation
J Clin Oncol 31, 2013 (suppl; abstr 606)
DOI
10.1200/jco.2013.31.15_suppl.606
Abstract #
606
Poster Bd #
9E
Abstract Disclosures
Similar Posters
Poster
2012 Breast Cancer Symposium
Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).
First Author: Farrah Datko
First Author: Nicholas Patrick McAndrew
Poster
2012 ASCO Annual Meeting
Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN).
First Author: Mothaffar F. Rimawi
Poster
2012 ASCO Annual Meeting
A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: An open-label, two-cohort, phase II study (VELVET).
First Author: Edith A. Perez